文献速递免疫规划

禽呼肠孤病毒muNS微球递送NS1蛋白联合改良痘苗病毒安卡拉株免疫后对非洲马瘟病毒的交叉保护免疫应答

Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
PubMed 文献 · Vaccine · 2019-11-07

研究将非洲马瘟病毒4型非结构蛋白1(NS1)载入禽呼肠孤病毒muNS蛋白微球(MS-NS1)和/或表达于重组改良痘苗病毒安卡拉株(MVA-NS1),在IFNAR(-/-)小鼠中评估同源MS-NS1或异源MS-NS1与MVA-NS1初免/加强的保护效果。结果显示MS-NS1与MVA-NS1免疫对同源AHSV-4感染提供完全保护,MS-NS1初免后MVA-NS1加强(MS-MVA-NS1)可诱导NS1特异性细胞毒性CD8+ T细胞,并在异源血清型AHSV-9攻击后预防非洲马瘟发病。

要点

  • MS-NS1与MVA-NS1联合免疫对同源AHSV-4感染提供完全保护。
  • MS-NS1初免、MVA-NS1加强可诱导NS1特异性细胞毒性CD8+ T细胞。
  • 该初免-加强方案在异源AHSV-9攻击后预防非洲马瘟发病。

核心结论

  • 基于MS-NS1和MVA-NS1的免疫对同源AHSV-4感染提供完全保护。
  • MS-NS1初免后MVA-NS1加强可诱导NS1特异性细胞毒性CD8+ T细胞,并在异源血清型AHSV-9攻击后预防非洲马瘟发病。
  • 由于非洲马瘟可由九种不同血清型引起,交叉保护免疫应答对通用多价疫苗至关重要。

研究设计与样本

  • 研究在IFNAR(-/-)小鼠中评估同源MS-NS1或异源MS-NS1与MVA-NS1初免/加强免疫对AHSV的保护效果。
  • 免疫原为载入禽呼肠孤病毒muNS蛋白微球的AHSV-4非结构蛋白1(MS-NS1)和/或重组改良痘苗病毒安卡拉株表达的NS1(MVA-NS1)。

主要发现

  • MS-NS1与MVA-NS1免疫对同源AHSV-4感染提供完全保护。
  • MS-NS1初免后MVA-NS1加强(MS-MVA-NS1)触发NS1特异性细胞毒性CD8+ T细胞。
  • MS-MVA-NS1免疫在IFNAR(-/-)小鼠中预防异源血清型AHSV-9攻击后的非洲马瘟发病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

African horse sickness virus (AHSV) is an insect-borne pathogen that causes acute disease in horses and other equids. In an effort to improve the safety of currently available vaccines and to acquire new knowledge about the determinants of AHSV immunogenicity, new generation vaccines are being developed. In this work we have generated and tested a novel immunization approach comprised of nonstructural protein 1 (NS1) of AHSV serotype 4 (AHSV-4) incorporated into avian reovirus muNS protein microspheres (MS-NS1) and/or expressed using recombinant modified vaccinia virus Ankara vector (MVA-NS1). The protection conferred against AHSV by a homologous MS-NS1 or heterologous MS-NS1 and MVA-NS1 prime/boost was evaluated in IFNAR (-/-) mice. Our results indicate that immunization based on MS-NS1 and MVA-NS1 afforded complete protection against the infection with homologous AHSV-4. Moreover, priming with MS-NS1 and boost vaccination with MVA-NS1 (MS-MVA-NS1) triggered NS1 specific cytotoxic CD8 + T cells and prevented AHSV disease in IFNAR (-/-) mice after challenge with heterologous serotype AHSV-9. Cross-protective immune responses are highly important since AHS can be caused by nine different serotypes, which means that a universal polyvalent vaccination would need to induce protective immunity against all serotypes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Marín-López A, Barreiro-Piñeiro N, Utrilla-Trigo S, et al. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Vaccine. 2019. PMID: 31708178. doi:10.1016/j.vaccine.2019.10.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。